The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.

Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported ...

Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its ...

Sanofi announced the findings in a statement and said it plans to soon publish the results in a medical journal. Sanofi and GSK are much more experienced in vaccine development than a number of ...

The Sanofi-GSK vaccine contains a laboratory-synthesized version of the coronavirus’s “spike” protein, which decorates the surface of the virus and is crucial to its ability to enter host cells.

Sanofi and Glaxo say their COVID-19 vaccine has 100% efficacy against severe disease and hospitalization, and they'll ask regulators for clearance.

If the study goes well, Sanofi and GlaxoSmithKline plan to launch a large-scale Phase 3 trial in the spring and seek regulatory approval in the second half of this year. The vaccine — which will ...

Sanofi agreed to buy UK vaccine developer Vicebio Ltd. for as much as $1.6 billion, as it seeks to expand in respiratory ...